Public Health | November 16, 2021
Biocon Biologics partners with RSSDI to expand insulin access
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Biocon Biologics and Viatris co-developed the products
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The centralized marketing authorization granted by the EC is valid in all EU Member
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
The standout story remains Wegovy, particularly its new oral formulation
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
The Danish biotech company confirmed the global study will begin in the second half of 2026
Subscribe To Our Newsletter & Stay Updated
